MEK Mutation clinical trials at UCSF

1 research study open to eligible people

Showing trials for

  • NST-628 Oral Tablets in Subjects with Solid Tumors

    open to eligible people ages 18 years and up

    This is a two-part Phase 1, open label, multi-center, single arm, non-randomized, multiple dose, safety, pharmacokinetic (PK) and preliminary efficacy study of single agent NST-628 in adult patients with MAPK pathway mutated/dependent advanced solid tumors who have exhausted standard treatment options.

    San Francisco, California and other locations

Our lead scientists for MEK Mutation research studies include .

Last updated: